Type of information: R&D agreement
Company: UCB (Belgium) Harvard University (USA)
Therapeutic area: CNS diseases - Immunology
Type agreement: research - R&D
Details: UCB and Harvard University have launched an innovative Research Alliance that creates a unique drug discovery bridge between industry and academia, with Harvard scientists continuing their research that holds potential for the development of new therapeutic modalities in clinical medicine. The strategy underlying the collaborative alliance is to advance ongoing Harvard research projects along the drug development pathway. The first research project funded under the Harvard-UCB alliance is a collaboration with Professor Gökhan S. Hotamisligil, M.D., Ph.D., Chair, Department of Genetics and Complex Diseases, Harvard School of Public Health, to generate and develop antibodies against an exciting target with potential application in a range of diseases including diabetes and metabolic disorders. UCB will bring its expertise in antibody generation and medicinal chemistry into the alliance. The collaboration focuses on central nervous system (CNS) and immunology, two key research domains for UCB.
Financial terms: UCB will bring its expertise in antibody generation and medicinal chemistry into the alliance and will provide up to $6 million over two years to fund specific innovative research projects led by Harvard scientists.